Saturday, October 24, 2026

NeOnc Breaks Through Brain Cancer Treatment with Intranasal Drug Delivery

Apr 7, 2026

NeOnc has developed the first platform that delivers chemotherapy directly to brain tumors through the nasal cavity, bypassing the blood–brain barrier and dramatically reducing systemic toxicity. Built on 179 global patents from USC Keck Medical School, the company is currently running four clinical trials, including three Phase II studies and a pediatric Phase I trial.

#NewToTheStreet #NeOnc #BrainCancer #Biotech #ClinicalTrials #IntranasalDelivery #CNSDrugs #OncologyInnovation #RareDiseases #PediatricCancer #FDAFastTrack #BiotechStocks #MedicalBreakthrough #PrecisionMedicine #NasdaqBiotech #CancerResearch #DrugDelivery #HealthcareInnovation #GrowthBiotech #InvestorInsights

Recommended

Stewards CEO Bilal Adam: Global Investment Strategy, Private Credit and Nasdaq Growth

Stewards CEO Bilal Adam: Global Investment Strategy, Private Credit and Nasdaq Growth

1 day ago
BioVie CEO: Promising Phase 2 Results for Long COVID and Parkinson’s Disease

BioVie CEO: Promising Phase 2 Results for Long COVID and Parkinson’s Disease

1 day ago
FreeCast CEO: How Its Streaming Software Platform Could Generate Multiple Revenue Streams

FreeCast CEO: How Its Streaming Software Platform Could Generate Multiple Revenue Streams

2 days ago
American Fusion Expands Texas Data Center Pipeline and Advances Texatron Testing Plans

American Fusion Expands Texas Data Center Pipeline and Advances Texatron Testing Plans

2 days ago
BioVie Reports Positive Phase 2 Parkinson’s Trial Results for Bezisterim in Key Patient Subgroup

BioVie Reports Positive Phase 2 Parkinson’s Trial Results for Bezisterim in Key Patient Subgroup

4 days ago
BioVie Reports Significant Long COVID Symptom Improvements in Phase 2 Clinical Trial

BioVie Reports Significant Long COVID Symptom Improvements in Phase 2 Clinical Trial

5 days ago
Open Page